» Articles » PMID: 17043166

Activation of the Cardiac Proteasome During Pressure Overload Promotes Ventricular Hypertrophy

Overview
Journal Circulation
Date 2006 Oct 18
PMID 17043166
Citations 98
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The adaptation of cardiac mass to hemodynamic overload requires an adaptation of protein turnover, ie, the balance between protein synthesis and degradation. We tested 2 hypotheses: (1) chronic left ventricular hypertrophy (LVH) activates the proteasome system of protein degradation, especially in the myocardium submitted to the highest wall stress, ie, the subendocardium, and (2) the proteasome system is required for the development of LVH.

Methods And Results: Gene and protein expression of proteasome subunits and proteasome activity were measured separately from left ventricular subendocardium and subepicardium, right ventricle, and peripheral tissues in a canine model of severe, chronic (2 years) LVH induced by aortic banding and then were compared with controls. Both gene and protein expressions of proteasome subunits were increased in LVH versus control (P<0.05), which was accompanied by a significant (P<0.05) increase in proteasome activity. Posttranslational modification of the proteasome was also detected by 2-dimensional gel electrophoresis. These changes were found specifically in left ventricular subendocardium but not in left ventricular subepicardium, right ventricle, or noncardiac tissues from the same animals. In a mouse model of chronic pressure overload, a 50% increase in heart mass and a 2-fold increase in proteasome activity (both P<0.05 versus sham) were induced. In that model, the proteasome inhibitor epoxomicin completely prevented LVH while blocking proteasome activation.

Conclusions: The increase in proteasome expression and activity found during chronic pressure overload in myocardium submitted to higher stress is also required for the establishment of LVH.

Citing Articles

Sacubitril/valsartan reduces proteasome activation and cardiomyocyte area in an experimental mouse model of hypertrophy.

Meyer-Jens M, Wenzel K, Grube K, Rudebusch J, Kramer E, Bahls M J Mol Cell Cardiol Plus. 2025; 7():100059.

PMID: 39802437 PMC: 11708427. DOI: 10.1016/j.jmccpl.2023.100059.


Psmb8 inhibits mitochondrial fission and alleviates myocardial ischaemia/reperfusion injury by targeting Drp1 degradation.

Su H, Xu L, Li P, Bi H, Jiang W, Li H Cell Death Dis. 2024; 15(11):803.

PMID: 39516219 PMC: 11549449. DOI: 10.1038/s41419-024-07189-1.


Comprehensive Proteomic Profiling of Human Myocardium Reveals Signaling Pathways Dysregulated in Hypertrophic Cardiomyopathy.

Lumish H, Sherrid M, Janssen P, Ferrari G, Hasegawa K, Castillero E J Am Coll Cardiol. 2024; 84(20):1999-2011.

PMID: 39365226 PMC: 11817648. DOI: 10.1016/j.jacc.2024.07.043.


Modulation of left ventricular hypertrophy in spontaneously hypertensive rats by acetylcholinesterase and ACE inhibitors: physiological, biochemical, and proteomic studies.

Hejnova L, Drastichova Z, Boros A, Hrdlicka J, Behuliak M, Neckar J Front Cardiovasc Med. 2024; 11:1390547.

PMID: 39355349 PMC: 11443425. DOI: 10.3389/fcvm.2024.1390547.


Genetic ablation of Lmp2 increases the susceptibility for impaired cardiac function.

Trogisch F, Koser F, Michel S, Liem D, Florea B, Hecker M Front Mol Biosci. 2024; 11:1148948.

PMID: 38516190 PMC: 10955435. DOI: 10.3389/fmolb.2024.1148948.